MAR 2 8 2002

PATENT

Atty. Docket No. PP00925.302

I hereby certify the paper is being deposited in the United States Postal Service as first class mail in an envelope addressed to the Assistant Commissioner of Patent and Trademarks, Washington, D.C.

20231 on March <u>19</u>,2002

Amanda Denise Willex Amanda D. Wilcox

Date

Narch 19,2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT:

MARK DE BOER et al.

SERIAL NO.:

09/954,764

GROUP ART UNIT: Unassigned

FILED:

September 18, 2001

EXAMINER: Unassigned

TITLE:

METHODS FOR BLOCKING B-CELL ACTIVATION USING ANT I-CD40

MONOCLONAL ANTIBODIES

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §1.97

Assistant Commissioner of Patents and Trademarks Washington, D.C. 20231

Sir:

The following is an Information Disclosure Statement submitted for the Examiner's consideration.

Applicants respectfully request that the Examiner review and make of record the documents identified below. A Form PTO-1449 listing the documents accompanies this paper. Applicants would appreciate the Examiner's initialing and returning the form to indicate that the documents have been reviewed and made of record.

The attached PTO 1449 form lists documents that were cited in a parent application, U.S. Serial No. 09/504,505, filed February 15, 2000 and, as such, copies thereof are not included pursuant to the provisions of 37 C.F.R. §1.98(d). However, Applicants have included a copy of reference C.65, which has not been previously cited.

PATENT Atty. Docket No. PP00925.302

This information disclosure statement is not intended as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that these citations constitute prior art under 35 USC §102.

The present information disclosure statement is being filed before the mailing date of the first Office Action on the merits and therefore no certification under 37 CFR §1.97(e) or fee under 37 CFR §1.17(p) is required. The office is hereby authorized to charge any additional fees which may be required by this paper, or to credit any overpayment, to our Deposit Account No. 03-1664

Respectfully submitted,

Dated: 3/15-10-2

Lisa E. Alexander Reg. No. 41,576

CHIRON CORPORATION Intellectual Property - R440 P.O. Box 8097 Emeryville, CA 94608 (510) 923-2585 Form PTO-1/449 (Rev. 8-83)

ATTY. DOCKET NO. PP00925.302/ 11862US09

SERIAL NO. 09/954,764

TION DISCLOSURE CITATION (Use several sheets if necessary)

APPLICANT(s): de Boer, et al.

FILING DATE September 18, 2001

GROUP ART UNIT: Not yet signed

			U.S. PATE	NT DOCUMENT	S		
EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DAPE OF SIF
	Al	4,355,023	10/19/82	Ehrlich et al.	424		
	A2	4,689,299	08/25/87	Insel et al.	435	240.27	8
	A3	4,886,796	12/12/89	Eichner et al.	514	211	
	A4	4,923,872	05/08/90	Kostlan et al.	514	258	
	A5	5,068,223	11/26/91	Lipsky et al.	514	019	
	A6	5,100,899	03/31/92	Calne	514	291	
	A7	5,182,368	01/26/93	Ledbetter et al.	530	388	
	A8	5,677,165	10/14/97	de Boer et al.	435	240.27	
	A9	5,874,082	02/23/99	de Boer	424	153.1	

	1		FOREIGN PAT	ENT DOCU	JMENT:	S		
EXAMINER INITIAL		DOCUMENT NO.	PUBLICATION DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	B1	0 434 879 A1	07/91	EPO				
	B2	0 555 880 A2	08/93	EPO				
	В3	WO 90/07861	07/90	PCT				
	B4	WO 93/08207	04/93	PCT				
	B5	WO 93/11794	06/93	PCT				
	B6	WO 94/01547	01/94	PCT			•	
	B7	WO 94/04570	03/92	PCT				
-	B8	WO 95/09653	04/95	PCT		-		
	В9	WO 92/00092	01/92	PCT				
	B10	WO 94/01457	01/94	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
	Cl	Armitage, et al., Molecular and Biological Characterization of a Murine Ligand for CD40, Nature 357:80-82 (May 7, 1992)					

FX	Al	M	IN	F	R

DATE CONSIDERED:

*EXAMINER: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 2 of 6 Form PTO-1449 U.S. PARTMENT OF COMMERCE PATER AND TRADEMARK OFFICE ATTY. DOCKET NO. SERIAL NO. (Rev. 8-83) 09/954,764 PP00925.302/ 11862US09 INFORMATION DISCOSURE CITATION APPLICANT(s): (Use several sheets if necessary) de Boer, et al. FILING DATE GROUP ART UNIT September 18, 2001 Not yet assigned

	16 2
C2	Banchereau, et al. Long-Term Human B Cell Lines Dependent on Interleukin-End
	Antibody to CD40, Science 251:70-72 (January 4, 1991)
C3	Banchereau, et al., Growing Human B Lymphocytes in the CD40 System, Nature
	353:678-679 (October 17, 1991)
C4	Chothia, et al., Canonical Structures for the Hypervariable Regions of Immunoglobulins,
	J. Mol. Biol. 196: 901-917 (1987)
C5	Claassen, et al., Mononuclear cells from patients with the hyper-IgE syndrome produce
	with IgE when they are stimulated with recombinant human interleukin-4, J. Allergy
	Clin., Immunol. 88:713-721 (1994)
C6	Clark, et al., Activation of Human B Cells Mediated Through Two Distinct Cell Surface
	Differentiation Antigens, Bp35 and Bp50, Proc. Natl. Acad. Sci. USA 83:4494-4498
	(June 1986)
C7	Clark, et al., Association Between IL-6 and CD40 Signaling IL0-6 Induces
	Phosphorylation of CD40 Receptors, J. Immunol. 145(5):1400-1406 (September 1, 1990)
C8	Cosimi, et al., Use of Monoclonal Antibodies to T-Cell Subsets for Immunologic
	Monitoring and Treatment in Recipients of Renal Allografts, N. Eng. J. Med. 305(6):308-
	313 (Aug. 6, 1981)
C9	de Boer, et al., Generation of Monoclonal Antibodies to Human Lymphocyte Cell Surface
	Antigens Using Insect Cells Expressing Recombinant Proteins, J. Immunol., Meth.
	152 :15-23 (1992)
C10	DeFranco, et al., Separate Control of B Lymphocyte Early Activation and Proliferation in
	Response to Anti-IgM Antibodies, The Journal of Immunology 135(1)87-94 (July 1985)
C11	DiSanto, et al., Generation of anti-human CD8\beta-specific antibodies using transfectants
	expressing mixed-species CD8 heterodimers, J. Immunol. Methods 141:123-131 (1991)
C12	Edgington, How Sweet it is: Selectin-Mediating Drugs, Biotechnology 10:383-389
	(1992)
C13	Fanslow, et al., CD40 MABS M2 and M3 inhibit CD40L Binding and Function, Tissue
	Antigens 42(3):304 (October 1993)
C14	Francisco, et al., Activity of a Single-Chain Immunotoxin that Selectively Kills
	Lymphoma and Other B-Lineage Cells Expressing the CD40 Antigen, Cancer Research
 	55 :3099-3104 (July 15, 1995)
C15	Freedman, et al., B7, A B Cell-Restricted Antigen that Identifies Preactivated B Cells,
	The Journal of Immunology 139 (10):3260-3267 (November 15, 1997)

EXAMINE	F
---------	---

DATE CONSIDERED:

^{*}EXAMINER: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 3 of 6 MAR 2 8 2002 PASENT AND TRADEMARK OFFICE Form PTO-1449 ATTY. DOCKET NO. SERIAL NO. (Rev. 8-83) 09/954,764 PP00925.302/ 11862US09 INFORMATION (Use several sheets if necessary) APPLICANT(s): de Boer, et al. FILING DATE GROUP ART Not yet assi September 18, 2001

	16 2
C16	Garrone, et al., mAb 104, a new monoclonal antibody, recognizes the Beantigen that is expressed on activated B cells and HTLV-1 transformed T cells, Immune 69:531-535 (1990)
C17	Gascan, et al., Anti-CD40 Monoclonal Antibodies or CD4 ⁺ T Cell Clones and IL-4 Induce IgG4 and IgE Switching in Purified Human B Cells Vai Different Signaling Pathways, The Journal of Immunology 147(1):8-13 (July 1, 1991
C18	Gauchat, et al., Modulation of IL-4 induced germline \in RNA synthesis in human B cells by tumor necrosis factor- α , anto-CD40 monoclonal antibodies or transforming growth factor- β correlates with levels of IgE production, International Immunology 4(3):397-406 (1991)
C19	Golub, Immunology a Synthesis, Sinauer Assoc. Inc., Sunderland, MA. pp 19-20 (1987)
C20	Gordon, et al., Resting B Lymphocytes can be Triggered Directly Through the CDw40 (Bp50) Antigen, A Comparison with IL-4-Mediated Signaling, The Journal of Immunology 140(5):1425-1430 (March 1, 1988)
C21	Gray, et al., Memory B Cell Development butnot Germinal Center Formation is Impaired by In Vivo Blockade of CD40-CD40 Ligand Interaction, J. Exp. Med. 180:141-155 (July, 1994)
C22	Gruber, et al., Anti-CD45 Inhibition of Human B Cell Proliferation Depends on the Nature of Activation Signals and the State of B Cell Activation, J. Immunol. 142(12):4144-4152 (June 15, 1989)
C23	Harris, et al., Therapeutic antibodies-the coming of age, Tibtech 11:42-44 (February 1993)
C24	Hartog, et al., Generation of a humanized anti-CD40 mab for treatment of autoimmune diseases. Immunotechnology 2(4):299 (November 1996) (abstract)
C25	Jabara, et al., CD40 and IgE: Synergism between Anti-CD40 Monoclonal Antibody and Interleukin 4 in the Induction of IgE Synthesis by Highly Purified Human B Cells, J. Exp. Med. 172:1861-1864 (December 1990)
C26	June, et al., Role of the CD28 Receptor in T-cell activation, Immunology Today 11(6):211-216 (1990)
C27	Jung, et al., Selective Inhibition of Growth Factor-Dependent Human B Cell Proliferation by Monoclonal Antibody AB1 to an Antigen Expressed by Activated B Cells, J. Exp. Med 160:1919-1924 (December 1984)

EXAMINER	DATE CONSIDERED:
*EXAMINER: Initial citation considered, whether or not citation is in conformance v considered. Include copy of this form with next communication to applicant.	vith MPEP 609; Draw line through citation if not in conformance and not

OIPE	•	Sheet 4 of
Form PTO-1449 (Rev. 8-83) MAR 2 8 2002 PATENT AND TRADEMARK OFFICE INFORMETION DISCLOSURE CITATION	ATTY. DOCKET NO. PP00925.302/ 11862US09	SERIAL NO. 09/954,764
(Use several sheets if necessary)	APPLICANT(s): de Boer, et al.	ECH CH
	FILING DATE September 18, 2001	GROUP ARE UNIT!

	± 20 <
C28	Kabat, et al., Sequences of Proteins of Immunological Interest, Tabulation and Analysis
	of Amino Acid and Nucleic Acid Sequences of Precursors, V-Regions, CO-Regions, J-
	Chain, β ₂ -Microglobulins, Major Histocompatibility Antigens, Thy-1, Complement, c-
	Reactive Protein, Thymopoietin, Post-gamma Globulin, and α_2 -Macroglobulin,
	sponsored through Contract NO1-RR-8-2118 by components of the National Institutes of
	Health, Bethesda, MD 20205 (1983)
C29	Kahan, Immunosuprressive therapy, Curr. Opin Immunology 4:553-560 (1992)
C30	Knight, et al., The Immunogenicity of the 7E3 Murine Monoclonal FAB Antibody
	Fragment Variable Region is Dramatically Reduced in Humans by Substitution of
	Human for Murine constant Regions, Molecular Immunology 32(16):1271-1281 (1995)
C31	Kriegler, et al., A Novel Form of TNF/Cachectin is a Cell Surface Cytotoxic
	Transmembrane Protein: Ramifications for the Complex Physiology of TNF, Cell 53:45-
	53 (1988)
C32	Kwekkeboom, et al., CD40 plays an essential role in the activation of human B Cells by
	Murine EL4B5 cells, Immunology 79:439-444 (1993)
C33	Lane, et al., Activated human T cells express a ligand for the human B Cell-associated
	antigen CD40 which participates in T cell-dependent activation of B lymphocytes, Eur. J.
	Immunol 22 :2573-2578 (1992)
C34	Ledman, et al., Anti-CD40 Monoclonal Antibody Blocks the Contract Dependent T
	Helper Signal Mediated by 5C8 Ag., Clinical Research 40:154A (1992)
C35	Linsley, et al., CTLA-4 is a Second Receptor for the B Cell Activation Antigen B7, J. Exp.
	Med. 174:561-569 (September 1991)
C36	Muraguchi, et al., Sequential Requirements for Cell Cycle Progression of Resting Human
	B Cells after Activation by Anti-Ig, The Journal of Immunology 132(1):176-180 (1984)
C37	Noelle, et al., T Helper Cells, Current Opinion in Immunology 4:333-337 (1992)
C38	Padlan, et al., A Possible Procedure for Reducing the Immunogenicity of Antibody
	Variable Domains While Preserving Their Ligand-Binding Properties, Molecular
	Immunology 28 (4/5):489-498 (1991)
C39	Paul (ED) Fundamental Immunology Raven Press NY 1993 Chapter 8: Immunogenicity
	and Antigen Structure page 242 only
C40	Paulie, et al., The Human B Lymphocyte and Carcinoma Antigen, CDw40, is a
	Phosphoprotein Involved in Growth Signal Transduction, J. Immunol. 142(2):590-595
	(January 15, 1989)
C41	PCT Written Opinion, International Application No. PCT/US97/02858 dated June 23,
	1997

E	X	A	M	ſΠ	N	F	R

DATE CONSIDERED:

*EXAMINER: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet	5	of 6	,
-------	---	------	---

OIFE		Sheet 5 of 6
(Rev. 8-83) MAR 2 8 7002 FATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION		SERIAL NO. 09/954,764
INFORMATION DISCLOSURE CITATION (Conserved and sheets if necessary)	APPLICANT(s): de Boer, et al.	APR 0
	FILING DATE September 18, 2001	GROUP ART UNT: 5 1 Not yet assiged 8 €
		22 7

C42	PCT Written Opinion, International Application No. PCT/US97/02958 dated November 21, 1997
C43	Ross, et al., Characterization of nerve growth factor receptor in neural crest tumors using monoclonal antibodies, Proc. Natl. Acad. Sci. USA 81:6681-6685 (November 1984)
C44	Rousset, et al., Cytokine-induced Proliferation and Immunoglobulin Production of Human B Lymphocytes Triggered through Their CD40 Antigen, J. Exp. Med. 173:705-710 (March 1991)
C45	Sato, et al., Biological Effects in Vitro of Monoclonal Antibodies to Human Epidermal Growth Factor Receptors, Mol. Biol. Med. 1:511-529 (1983)
C46	Splawski, et al., Immunoregulatory Role of CD40 In Human B Cell Differentiation, The Journal of Immunology 150:1276-1285 (February 15, 1993)
C47	Stamenkovic et al., A B-lymphocyte Activation Molecule Related to the Nerve Growth Factor Receptor and Induced by Cytokines in Carcinomas, EMBO Journal 8(5):1403-1410 (1989)
C48	Stuber, et al., Blocking the CD40L-CD40 Interaction in vivo specifically prevents the priming of T Helper 1 Cells through the inhibition of Interleukin 12 Secretion, J. Exp. Med. 183:693-698 (1996)
C49	Tanaka, et al., Distinct Reactivities of four Monoclonal Antibodies with Human Interleukin 2 Receptor, Microbial. Immunol. 29(10):959-972 (1985)
C50	Uckun, et al., Temporal Association of CD40 Antigen Expression with Discrete Stages of Human B-Cell Ontogeny and the Efficacy of Anti-CD40 Immunotoxins Against Clonogenic B-Lineage Acute Lymphoblastic Leukemia as Well as B-Lineage Non-Hodgkin's Lymphoma Cells, Blood 76(12):2449-2456 (December 15, 1990)
C51	Valle, et al., mAb 104, A New Monoclonal Antibody, Recognized the B7 Antigen that is Expressed on Activated B Cells HTLV-1-Transformed T Cells, Immunology, 69:531-535 (1990)
C52	Ward, et al., Blocking of adhesion molecules in vivo as anti-inflammatory therapy, Therapeutic Immunology 1:165-171 (1994)
C53	Webb, et al., Cell-Surface Expression and Purification of Human CD4 Produced in Baculovirus-Infected Insect Cells, Proc. Natl. Acad. Sci. USA 86:7731-7735 (October 1989)
C54	Wetzel, et al., Evidence for Two Distinct Activation States Available to B Lymphocytes, The Journal of Immunology 133(5):2327-2332 (November 1984)
C55	Winter, et al., Antibody-based Therapy, Humanized Antibodies, TIPS 14:139-143 (1993)

T73/		FT	n T	r	-
		11		н	к

DATE CONSIDERED:

*EXAMINER: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Ch	eet	~	۰£	_
->n	eer	n	nΤ	n

OIPE		Sheet 6 of 6
(Rev. 8-83) WAR 2 8 2002 INFORMATION DISCLOSURE CITATION	ATTY. DOCKET NO. PP00925.302/ 11862US09	SERIAL NO. 09/954,764
(Use appeal all sheets if necessary)	APPLICANT(s): de Boer, et al.	
	FILING DATE September 18, 2001	Not yet assigned O
		田 5 川
C56 Yellin, et al., CD40 Molecules Induce Surface T Cell-B Cell Activating Mole	Down-Modulation and accule/CD40-L, J. of Imm	Endocytosi of Tell unology 15 398 608

C56	Yellin, et al., CD40 Molecules Induce Down-Modulation and Endocytosis of Tell Surface T Cell-B Cell Activating Molecule/CD40-L, J. of Immunology 1525 98 608 (1994)
C57	Zhang, et al., CD40 Stimulation Provides an IFN-γ-Independent and IL-4 Dependent Differentiation Signal Directly to Human B Cells for IgE Production, Journal of Immunology 146(6):1836-1842 (March 15, 1991)
C58	Boussiotis, et al., Activated Human B Lymphocytes Express Three CTLA-4 Counterreceptors That Costimulate T-Cell Activation, Proc. Natl. Acad. Sci. USA 90:11059-11063 (December, 1993)
C59	de Boer, et al., Functional Characterization of a Novel Anti-B7 Monoclonal Antibody, Eur. J. Immunology 22 (12):3071-3075 (December, 1992)
C60	Freeman, et al., B7,. A New Member of the Ig Superfamily with Unique Expression on Activated and Neoplastic B Cells, The Journal of Immunology, 143(8):2714-2722 (October 1989)
C61	Freeman, et al., Cloning of B7-2: A CTLA-4 Counter-Receptor That Costimulates Human T Cell Proliferation, Science 262:909-911 (1993)
C62	Jenkins, et al., Antigen Presentation by chemically Modified Splenocytes Induces Antigen-Specific T Cell Unresponsiveness in Vitro and in Vivo, Journal of Experimental Medicine 165:302-319 (February 1987)
C63	Jenkins, et al., Molecular Events in the Induction of a Nonresponsive State in Interleukin 2-Producing Helper T-Lymphocyte Clones, Proc. Natl. Acad. Sci. USA 84:5409-5413 (August 1987)
C64	Vandenberghe et al., In situ Expression of B7/BB! On Antigen-Presenting cells and activated B Cells: an Immunohistochemical study International Immunology 5(3):317-321 (March 1993)
C65	Dancescu et al., IL-4 Induces Conformational change of CD20 Antigen Via A Protein Kinase C-Independent Pathway 148(8):2411-2415 (April 1992)

DATE CONSIDERED:

*EXAMINER: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.